CA-DENODO
22.5.2024 13:01:32 CEST | Business Wire | Press release
Denodo, a leader in data management, announced that the company is expanding its efforts to provide energy and utility companies with the necessary data management capabilities to gain advanced capabilities and meet new renewable energy requirements, all while remaining in compliance with increasingly stringent regulatory demands.
Facing numerous challenges, including generating, managing, and consuming new, decarbonized and increasingly digitized sources of energy; maintaining resilience and sustainability in a time of change; developing new technologies such as virtual power plants (VPPs) based on intelligent operations; all while managing a rising number of environmental, social, and governance (ESG) and sustainability initiatives; energy and utility companies need to be able to manage data so that it helps to overcome these challenges, rather than adding to them.
The Denodo Platform facilitates this by providing real-time access to data across myriad distributed energy resources, while enabling the establishment of a unified semantic layer over all data sources, to deliver data when it is needed, in the language required by each data consumer. This provides energy and utility companies with the foundation to overcome myriad known and unknown challenges. The Denodo Platform enables such capabilities as continuous monitoring and control, and makes it possible for VPP operators to make fast, informed decisions in response to changes in energy demand, pricing, and environmental conditions. By enabling such capabilities, the Denodo Platform provides energy and utility companies with a reliable foundation for innovation.
Denodo has a strong heritage in providing impactful data management solutions to energy and utility companies, such as VTTI, a Netherlands-based energy storage and developer of critical energy infrastructure; BHP, a global resources company headquartered in Melbourne, Australia; Engie Mexico, an energy company that is committed to bringing energy to the people of Mexico; and Suez, a French multinational corporation with operations in water, electricity, natural gas supply, and waste management.
Hans Geurts, chief information officer for VTTI, says, “As a rapidly growing organization in an uncertain geopolitical environment, laying a strong data foundation was critical for us to become data-driven. The Denodo Platform has helped us in simplifying and standardizing our data infrastructure, while boosting our business resilience.” The Denodo Platform acts as VTTI’s single source of truth for enterprise resource planning (ERP) data. The company leverages it to synthesize, combine, and analyze operational insights to improve ways of working and address inefficiencies in the operational micro-steps at the company’s terminals. It also helps VTTI to visualize and understand product trade flows through the terminals and various modes of transport, helping VTTI’s commercial teams to better serve customers.
Joshua Fletcher, superintendent HSE, Reporting at BHP, made similar statements about the effect that the Denodo Platform had on the company’s business. “The Denodo Platform helps us to reduce the overall size of the data sets that need to be moved over the network. It helped us to create a logical data fabric that makes our data assets reusable and can be consumed by users spread across the globe.”
Luis Guadarrama, senior manager, Data Analytics and Innovation at Engie Mexico, says, “The Denodo Platform delivers data quickly and easily, which helps us to deliver value to the business and democratize data access. Our business users might not understand the technical part, but they do understand that there’s something called ‘the Denodo Platform’ that helps them to connect to data in an easier way, to make better decisions.” Engie Mexico leveraged the Denodo Platform to enable a variety of strategic initiatives, including web services that help hundreds of thousands of customers to balance their use of natural gas, chatbots that assist in problem resolution, and machine learning (ML) algorithms that analyze the behavior patterns of business-to-consumer gas customers.
Denodo believes that VPPs are the power plants of the future. VPPs can run energy in the cloud, and they can supply renewable energy on-demand, through innovative web-based interfaces that can remotely link and manage homes with solar and battery storage. Additionally, VPPs can feed power back to the grid during peak times, to relieve the load and keep the network stable.
Denodo also believes that data-driven, intelligent operations is a critical capability that can greatly assist utility CIOs in designing fit-for-the-future assets that bridge physical and digital phenomena. The Denodo Platform facilitates the development of intelligent operations and VPPs through diverse capabilities, including distributed energy resource management, predictive analytics for maintenance, and optimization of energy assets.
“Advanced data management technology will be essential in enabling new capabilities that oil and gas companies need to thrive, both now and beyond the energy transition,” said Paul Moxon, SVP Data Architecture and Chief Evangelist at Denodo. “Power plants of the future will operate in an eco-centric, distributed manner, enabling the data-driven, intelligent VPPs of the future. The Denodo Platform, with its ability to provide real-time data access to increasingly diverse data sources, will underpin success by providing energy and utility business users with access to data at the speed of business.”
For more information:
- Denodo in Energy & Utilities
- Seeking a Data-Driven Transformation: Challenges and Opportunities in the Energy and Utilities Industry
- Case Study: Total SE
- Webinar: Suez
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading logical data management platform for delivering data in the language of business, at the speed of business, for all data-related initiatives across the organization. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across enterprises in 30+ industries all over the world have received payback in less than six months. For more information, visit denodo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240522149387/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
